Related Experiment Video
Updated: Feb 27, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.6K
An Update on Anticoagulation in Atrial Fibrillation
1Deakin University, Geelong, Vic, Australia.
Heart, Lung & Circulation
|July 8, 2017
Summary
Direct-acting oral anticoagulants (DOACs) offer a new approach to preventing strokes in atrial fibrillation (AF) patients. DOACs are expected to become the primary stroke prevention therapy for non-valvular AF.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) increases stroke risk, necessitating anticoagulation.
- Warfarin was the standard anticoagulant for stroke prevention in AF.
- Novel direct-acting oral anticoagulants (DOACs) have emerged as alternatives.
Purpose of the Study:
- To discuss the paradigm shift in anticoagulation therapy for AF.
- To highlight the role of DOACs in stroke prevention.
- To guide physicians on current anticoagulation strategies for AF.
Main Methods:
- Review of current anticoagulation guidelines and clinical evidence.
- Comparison of warfarin with DOACs for stroke prevention in AF.
- Analysis of treatment philosophy changes in AF management.
Main Results:
- DOACs represent a significant advancement in stroke prevention for AF.
- The focus of treatment decisions is shifting from 'when to use' to 'when not to use' anticoagulation.
- Warfarin remains relevant for specific patient subgroups.
Conclusions:
- DOACs are poised to become the predominant therapy for stroke prevention in non-valvular AF.
- Physicians must adapt to new treatment algorithms considering DOACs.
- Anticoagulation management in AF has entered a new era with DOAC availability.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
410
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
410
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:16Clot Retraction and Fibrinolysis
9.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.6K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
553
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
553